Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer

Whether primary prophylactic pegylated‐granulocyte‐colony stimulating factor (PEG‐G‐CSF) should be administered immediately after the initiation of ramucirumab plus docetaxel (DR) to prevent the occurrence of febrile neutropenia (FN) is unclear. Our retrospective study aimed to elucidate whether PEG...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouri, Atsuto, Kaira, Kyoichi, Shiono, Ayako, Yamaguchi, Ou, Murayama, Yoshitake, Kobayashi, Kunihiko, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449259/
https://www.ncbi.nlm.nih.gov/pubmed/30859745
http://dx.doi.org/10.1111/1759-7714.13022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449259/
https://www.ncbi.nlm.nih.gov/pubmed/30859745
http://dx.doi.org/10.1111/1759-7714.13022

Ejemplares similares